Effective with date of service Feb. 28, 2022, the Medicaid and NC Health Choice programs cover cabotegravir extended-release injectable suspension, for intramuscular use (Apretude).
Effective April 1, 2022, NC Medicaid coverage for pregnant beneficiaries will extend to the last day of the month in which the 12-month postpartum period ends.